RETINNOVATE

EQUIPPING RETINAL DISEASE INNOVATORS FOR MARKET SUCCESS

EVENT PARTNERS

ASSESS

MEDINECT OPHTHO

13TH-14TH NOV, 2025 • QUEEN'S UNIVERSITY BELFAST, LANYON BUILDING

SPONSORS WELCOME: ENQUIRIES@FLOWCOEVENTS.COM

DAY 1 FLOW

THURSDAY 13TH NOVEMBER 2025

8.30 AM **WELCOME AND KEYNOTE**	REGISTRATION From Market to Bench. A reverse engineered approach to innovation.
9:30 AM **SESSION 1** **PRECLINICAL RESEARCH: DESIGNING WITH PURPOSE I**	Strategies for ensuring translational relevance from the outset. Model selection, species choice, and study endpoints aligned to clinical goals.
11:30 AM **SESSION 2** **PRECLINICAL RESEARCH: DESIGNING WITH PURPOSE II**	A data package for smooth clinical progression: Designing robust, reproducible studies that meet regulatory and investor expectations. .
2:00 PM **SESSION 3** **INTELLECTUAL PROPERTY**	IP milestones from discovery to market: Strategies for building defensible, value-driving patent portfolios.
3:00 PM **SESSION 4** **TARGET PRODUCT PROFILE I**	Target Product Profile as a strategic roadmap: Key components, regulatory considerations, and methods for shaping a competitive product vision.
4:30 PM **SESSION 5** **TARGET PRODUCT PROFILE II**	**Exercise**: Developing a TPP framework. Defining critical attributes, differentiators, and pathways to regulatory and commercial success.

DRINKS RECEPTION

Join us for an evening reception with attendees of this years EVICR.net conference to meet industry- and investigator-led clinicians that will play a critical role in your journey to clinic.

LOCATION TBC

DAY 2 FLOW

FRIDAY 14TH NOVEMBER 2025

8.30 AM
WELCOME AND RECAP

Reflections on clinician networking.
Feedback, clinical perspectives, and how they shape development priorities.

9:30 AM
SESSION 1
REGULATORY PATHWAY FOR RETINAL THERAPEUTICS I

Regulatory routes for small molecules, biologics, and retinal devices.
Key agency expectations, submission strategies, and approval timelines.

11:30 AM
SESSION 2
REGULATORY PATHWAY FOR RETINAL THERAPEUTICS II

Navigating ATMP classification.
Frameworks for gene and cell therapies in ophthalmology. Regulatory innovation tools, and global harmonisation challenges.

2:00 PM
SESSION 3
MARKET ACCESS I

Aligning clinical and economic value.
Key hurdles in securing reimbursement and market entry.

3:00 PM
SESSION 4
MARKET ACCESS II

How HTA insights shape development:
Leveraging early data to strengthen your value propositions, optimise pricing and secure investment.

4:30PM
SESSION 5
THE RETURN ON INVESTMENT IN EARLY HTA

Health technology assessment and de-risking R&D.
Maximizing long-term expected value by integrating HTA from the start.

5:30 PM
NETWORKING DRINKS

Following the closing session, drinks will be offered and calendars open for networking

"YOU COULD HAVE AN INCREDIBLY EFFECTIVE DRUG, BUT IF PAYERS WON'T PAY, IT WILL NEVER REACH THE PATIENTS WHO NEED IT"

PROF. CHRIS MCCABE, HEALTH ECONOMIST

'ONE (VERY) LONG COFFEE WITH CHRIS MADE ME REALISE WE NEEDED TO CREATE SOMETHING TO HELP DRUG DEVELOPERS THINK LIKE LATE-STAGE INVESTORS BY PROVIDING VALUE AND INSIGHT THAT IS DIFFICULT TO FIND OR TOO EXPENSIVE - FROM THERE, **RETINNOVATE** WAS FOUNDED'

DR. JAMES BOJDO, PROGRAMME DIRECTOR

RETINNOVATE bridges the gap between scientific innovation and commercial success. Our bootcamp brings together experts in preclinical modelling, regulatory strategy, IP, health economics, and investment to give retinal disease innovators the tools to improve investor onboarding and increase the chances of success — not just in navigating the pathway to treating patients, but in navigating the different market payers.

REGISTRATION NOW OPEN FOR 2025 COHORT

Early-bird registration - Closing date 20th July 2025	**Academic €499**	**Industry €799**	**Investors €1299**
Standard registration - Closing date 20th September 2025	**Academic €899**	**Industry €1299**	**Investors €1999**

Early applications are encouraged. Applications will be assessed within three weeks of submission.

WEBSITE

FOR ENQUIRIES

CONTACT
ENQUIRIES@FLOWCOEVENTS.COM

APPLY HERE